Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric cefiderocol safety, tolerability, and pharmacokinetics study in Gram-negative infections
2019-002121-30Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cefiderocol in complicated urinary tract infection (cUTI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 4 more (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Pharmacokinetics and Safety and tolerability after single dose. Started Nov 2019; status: completed.
02
Drugs
cefiderocol
03
Conditions
complicated urinary tract infection (cUTI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)sepsis
Beyond the preview
Go deeper on 2019-002121-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002121-30.